Vincristine added to glucocorticoids in dogs with immune-mediated thrombocytopenia — POSSIBLE

In dogs with immune-mediated thrombocytopenia, does adding a single dose of vincristine to glucocorticoids vs glucocorticoids alone shorten time to platelet recovery and hospitalisation?

Shelf #369 · gate-verified and approved by the developer

POSSIBLE: The direct evidence is one small prospective controlled study that was not randomised as far as its record establishes. Rozanski 2002 (24 bleeding dogs with severe primary immune-mediated thrombocytopenia, all on immunosuppressive prednisone) found dogs also given a single IV dose of vincristine 0.02 mg/kg reached a platelet count of ≥ 40,000/µL faster (mean 4.9 ± 1.1 vs 6.8 ± 4.5 days) and were hospitalised for less time (5.4 ± 0.3 vs 7.3 ± 0.5 days, as printed in the record) than dogs on prednisone alone, with no adverse effects attributed to vincristine. A later randomised trial (Balog 2013) did not compare vincristine against glucocorticoids alone, but vincristine-treated dogs — all also on corticosteroids — recovered at the same median speed (2.5 days) as dogs given human IV immunoglobulin, an adjunct that a randomised double-blind placebo-controlled trial (Bianco 2009) had shown beats corticosteroids alone (median recovery 3.5 vs 7.5 days, P = .018; median hospitalisation 4 vs 8 days, P = .027). That indirect chain is consistent with vincristine speeding recovery by roughly two days, but the claim-carrying comparison is small and its allocation method is not established, so the stamp is POSSIBLE, not higher — and it is a platelet-recovery and hospitalisation claim, not a survival claim. Drafted Nov 10, 2026 (VetMed build, topic #369); all figures from abstracts fetched and verified at drafting.

Rozanski 2002: prednisone + single-dose vincristine vs prednisone alone — platelet recovery 4.9 vs 6.8 days, hospitalisation 5.4 vs 7.3 days

Prospective controlled clinical trial (indexed Controlled Clinical Trial — the record does not establish randomisation or blinding)

Who: Dogs: 24 bleeding dogs with severe primary immune-mediated thrombocytopenia at a university referral hospital — all dogs received immunosuppressive prednisone (1.5 to 2 mg/kg PO every 12 h); 12 dogs additionally received a single dose of vincristine (0.02 mg/kg IV), and dogs in the prednisone-alone group that failed to respond received one dose of vincristine on day 7. A response was defined as an increase in platelet count to ≥ 40,000/µL; platelet count, transfusion requirement and outcome were monitored.

Result: Dogs that received prednisone and vincristine had a significantly faster increase in platelet count to ≥ 40,000 platelets/µL than dogs that received prednisone alone (mean ± SD, 4.9 ± 1.1 vs 6.8 ± 4.5 days, respectively). A similarly rapid response was observed in dogs that received vincristine on day 7 after treatment with prednisone alone had failed. Duration of hospitalization was reduced in the vincristine group compared with the prednisone group (5.4 ± 0.3 vs 7.3 ± 0.5 days, respectively, as printed in the record). No adverse effects attributable to vincristine were observed in any dog. The record concludes early use of vincristine seems warranted in dogs with severe primary IMT.

Watch out: The record — publication type Controlled Clinical Trial, described in its own abstract as a 'prospective case study' — nowhere establishes that dogs were randomised or that assessors were blinded, so allocation bias cannot be excluded in a 24-dog study; no benefit of the doubt is taken on either design element. The hospitalisation standard deviations as printed (± 0.3 and ± 0.5 days) are unusually tight for this outcome and are quoted exactly as the record gives them. Survival is not an endpoint of this shelf's claim.

Rozanski EA, Callan MB, Hughes D, Sanders N, Giger U. Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. J Am Vet Med Assoc. 2002;220(4):477-81. PMID: 11860242. Registry ID: none in the record. MeSH: Animals · Blood Platelets · Dog Diseases · Dogs · Drug Therapy, Combination · Female · Glucocorticoids · Male · Platelet Count · Prednisone · Prospective Studies · Thrombocytopenia · Treatment Outcome · Vincristine

Balog 2013: vincristine vs human IV immunoglobulin, both on corticosteroids — median platelet recovery 2.5 days in both groups (P = .51)

Prospective randomized clinical trial vs an active adjunct (indexed Randomized Controlled Trial — no placebo/steroids-alone arm)

Who: Dogs: 20 dogs with idiopathic immune-mediated thrombocytopenia (platelet count < 16,000/µL) at a university referral hospital — all dogs were treated with corticosteroids and randomly assigned to a single dose of human intravenous immunoglobulin (hIVIG, 0.5 g/kg; n = 10) or vincristine (VINC, 0.02 mg/kg; n = 10); outcome measures were platelet recovery time, duration of hospitalization and survival to discharge.

Result: There was no significant difference in age, sex, weight or initial platelet count between the groups. Median platelet recovery time for both groups was 2.5 days (P = .51). Median hospitalization time for all dogs that survived to discharge was 4 days and was not different between groups (P = .29). Seven of 10 dogs in the hIVIG group and 10 of 10 in the VINC group survived to discharge; survival analysis identified no significant difference between groups at discharge, 6 months or 1 year. No adverse effects were reported in either group. The record concludes vincristine should be the first-line adjunctive treatment because of lower cost and ease of administration compared with hIVIG.

Watch out: This randomised trial never compares vincristine with corticosteroids alone — it shows vincristine performs like hIVIG, which is only evidence for this shelf's question when read together with Bianco 2009 (below), where hIVIG beat corticosteroids alone. The 10-of-10 vs 7-of-10 survival-to-discharge split was not statistically significant and must not be quoted as a survival benefit; this shelf makes no survival claim. Blinding is not established by the record.

Balog K, Huang AA, Sum SO, Moore GE, Thompson C, Scott-Moncrieff JC. A prospective randomized clinical trial of vincristine versus human intravenous immunoglobulin for acute adjunctive management of presumptive primary immune-mediated thrombocytopenia in dogs. J Vet Intern Med. 2013;27(3):536-41. PMID: 23527952. Registry ID: none in the record. MeSH: Animals · Antineoplastic Agents, Phytogenic · Blood Platelets · Dog Diseases · Dogs · Drug Therapy, Combination · Glucocorticoids · Humans · Immunoglobulins, Intravenous · Immunologic Factors · Purpura, Thrombocytopenic, Idiopathic · Vincristine

Bianco 2009: hIVIG + corticosteroids vs corticosteroids alone — median platelet recovery 3.5 vs 7.5 days (P = .018), hospitalisation 4 vs 8 days (P = .027)

Prospective, randomized, double-blinded, placebo-controlled clinical trial of the comparator adjunct hIVIG (indexed Randomized Controlled Trial, with MeSH Double-Blind Method) — carded as the anchor for the indirect comparison, not as vincristine evidence

Who: Dogs: 18 client-owned dogs with a presumptive diagnosis of primary immune-mediated thrombocytopenia at a university referral hospital — randomised to a single human intravenous immunoglobulin infusion (hIVIG, 0.5 g/kg) or placebo, as adjunctive treatment alongside corticosteroids; dogs were followed for adverse reactions over a 6-month period.

Result: The median platelet count recovery time for the hIVIG group was 3.5 days (mean ± SD: 3.7 ± 1.3 days; range, 2-7 days) and 7.5 days for the placebo group (mean ± SD: 7.8 ± 3.9 days; range, 3-12 days), a significant reduction in platelet count recovery time (P = .018). The median duration of hospitalization was 4 days for the hIVIG group (mean ± SD: 4.2 ± 0.4 days; range, 2-8 days) and 8 days for the placebo group (mean ± SD: 8.3 ± 0.6 days; range, 4-12 days), a significant reduction (P = .027). There were no identifiable immediate or delayed adverse reactions to hIVIG over 6 months, and no significant difference between groups in the expense of initial patient care.

Watch out: This trial is about hIVIG, not vincristine: it is carded because Balog 2013's vincristine-equals-hIVIG result only supports this shelf through it, and indirect chains are weaker than the direct comparison. Anchor correction: the draft cited 'Bianco et al. 2009' as a randomised vincristine study — the genuine Bianco 2009 record is this hIVIG trial; the randomised vincristine trial is Balog 2013.

Bianco D, Armstrong PJ, Washabau RJ. A prospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs. J Vet Intern Med. 2009;23(5):1071-8. PMID: 19674280. Registry ID: none in the record. MeSH: Adrenal Cortex Hormones · Animals · Dog Diseases · Dogs · Double-Blind Method · Female · Humans · Immunoglobulins, Intravenous · Infusions, Intravenous · Male · Platelet Count · Prospective Studies · Purpura, Thrombocytopenic, Idiopathic

Synthesis: one small non-randomised direct study says about two days faster; a randomised indirect chain points the same way

Synthesis

Who: Synthesis of the cards above: Rozanski 2002 (prospective controlled trial, 24 bleeding dogs with severe primary IMT, prednisone ± single-dose vincristine); Balog 2013 (prospective randomised trial, 20 dogs, vincristine vs hIVIG on corticosteroids); Bianco 2009 (randomised double-blind placebo-controlled trial, 18 dogs, hIVIG vs placebo on corticosteroids).

Result: The direct comparison (Rozanski) gives vincristine roughly a two-day advantage in time to platelet count ≥ 40,000/µL (4.9 vs 6.8 days) and in hospitalisation (5.4 vs 7.3 days), and dogs failing prednisone alone responded rapidly when vincristine was added on day 7. The randomised evidence is one step removed — vincristine matched hIVIG (Balog), and hIVIG beat steroids alone (Bianco) — but it points the same direction and no carded record points the other way. With no adverse effects attributed to the single dose in any carded record, adjunctive vincristine is a reasonable, cheap intervention whose recovery-speed benefit is POSSIBLE on this evidence: real enough to use, not proven enough to promise, and silent on survival.

Watch out: Every carded study is small (18-24 dogs) and from referral populations with presumptive or primary IMT; dogs with secondary thrombocytopenia or different severity may not behave the same. Later vincristine harms literature exists outside this question's records (e.g. neutropenia case series) and is not carded here — 'no adverse effects observed' applies only within these three small trials.

Synthesis of Rozanski EA et al. PMID: 11860242; Balog K et al. PMID: 23527952; Bianco D et al. PMID: 19674280. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.